Medtronic plc filings document material events, capital structure, registered securities, governance matters, and operating and financial disclosures for a medical-device company organized in Ireland. The 8-K record identifies MDT ordinary shares and multiple series of senior notes listed on the New York Stock Exchange, alongside current reports used for company events and financial-result communications.
The filing record also includes exchange and registration status for debt securities, including a Form 25 notice tied to removal from listing and registration of a guarantor class of senior notes. These disclosures frame Medtronic's public-company obligations around equity, debt instruments, material agreements, and regulatory or clinical developments.
Medtronic plc President Michael Marinaro acquired 6,547 restricted stock units on November 2, 2026; his directly held ordinary shares following the award totaled 113,353. The units vest 100% on August 3, 2029.
He also received 16,367 performance share units at target. Depending on performance metrics over a three-year period, 39,281 shares will be issued if maximum metrics are achieved, while the units may vest at 0 shares if minimum metrics are not met. Certain performance conditions will have been satisfied on April 27, 2029. The 42,994 stock options have a $99.29 exercise price; 25% of the shares granted become exercisable per year beginning August 3, 2027, and the options expire November 2, 2036.
Kevin E. Lofton reported disposition transactions in this Form 4 filing. Medtronic plc (MDT) director Kevin E. Lofton had 182 ordinary shares accepted for exchange in Medtronic’s MiniMed exchange offer on October 15, 2026. He received 836 MiniMed common shares at a final exchange ratio of 4.5939 MiniMed shares for each Medtronic share. His reported Medtronic holdings after the transaction were 9,977 ordinary shares, including 19 shares acquired through dividend reinvestment since his last report.
Medtronic plc (MDT) completed its separation of MiniMed Group, Inc. after the exchange offer settled. Medtronic elected to exchange its remaining 252,813,348 MiniMed common shares in the offer, which was 5.4x subscribed.
The board appointed Michael Marinaro, Executive Vice President and President, Medical Surgical Portfolio, Americas, and Global Commercial Operations, as President, Medtronic, effective October 14, 2026. He retains his current responsibilities and adds oversight responsibility for Greater China, which Alex Gu, Senior Vice President and President, Greater China, continues to manage locally.
For fiscal 2027, Marinaro’s annual base salary increased to $1,000,000, and his target annual incentive remains 100% of base salary. Supplemental long-term awards, to be granted November 2, 2026, have an aggregate target value of approximately $3.25 million. Shareholders elected 12 directors, ratified the auditor appointment in a non-binding vote, approved named-executive compensation in a non-binding advisory vote, and approved the share-authority and overseas-purchase proposals.
Medtronic plc (MDT) EVP, Pres MedSurg and Americas Michael Marinaro sold 10,420 ordinary shares at $96 per share on October 15, 2026. The sale was made pursuant to a Rule 10b5-1 plan adopted by Michael Marinaro on March 17, 2026. He reported 105,916 ordinary shares held directly after the sale.
Medtronic plc (MDT) Chairman and CEO Geoffrey Martha reported a direct sale of 50,000 ordinary shares on October 15, 2026, at $95 per share. After the sale, he directly held 277,866 ordinary shares. The sale was made pursuant to a Rule 10b5-1 plan adopted on July 16, 2026. The transaction is described as a sale in the open market or a private transaction.
Medtronic plc officer Michael Marinaro is listed for a proposed sale of 10,420 common shares, with an aggregate market value of $1,000,320.00. Fidelity Brokerage Services LLC is listed as the broker, and the approximate sale date is October 15, 2026. The security history includes prior ESPP purchases, dividend reinvestments, restricted-stock vesting and a stock-option exercise.
Medtronic plc (MDT) is the issuer named in a Rule 144 notice for a proposed sale of 50,000 common shares. The account-holder field reads “Martha Geoffrey,” while the signature identifies Geoffrey Martha. The notice lists an aggregate market value of $4,750,000, Fidelity Brokerage Services LLC as broker, and an approximate sale date of October 15, 2026; the share history lists restricted-stock vesting and a stock-option exercise.
Medtronic plc completed its exchange offer, accepting 55,032,401 Medtronic ordinary shares in exchange for 252,813,348 newly issued MiniMed common shares and disposing of all its remaining interest in MiniMed. The offer expired October 9, 2026, and was oversubscribed; 297,521,390 Medtronic shares were validly tendered. A final 18.289133% proration factor applied to shares subject to proration, while all valid tenders from eligible odd-lot holders were accepted.
Medtronic plc (MDT) announced final results of its exchange offer, under which it will exchange its remaining 252,813,348 MiniMed Group, Inc. common shares for 55,032,401 Medtronic ordinary shares. The oversubscribed offer expired October 9, 2026.
Of 297,521,390 Medtronic shares validly tendered and not withdrawn, 55,032,401 will be accepted. A final 18.289133% proration factor applies to other valid tenders; shareholders who owned fewer than 100 Medtronic shares and tendered all of them will not be subject to proration. Following completion, Medtronic will retain no MiniMed common shares, and shareholders whose Medtronic shares are accepted will receive newly issued MiniMed shares.
Medtronic plc’s exchange offer expired on October 9, 2026, and was oversubscribed. Based on a preliminary count, 298,024,452 Medtronic ordinary shares were validly tendered and not validly withdrawn; Medtronic intends to accept 55,032,401 of them in exchange for 252,813,348 MiniMed Group common shares. The estimated preliminary proration factor for shares subject to proration is approximately 18.3% if all shares tendered by notice of guaranteed delivery are delivered under the offer terms, and may change based on how many satisfy those procedures.